journal
MENU ▼
Read by QxMD icon Read
search

Lancet Neurology

journal
https://www.readbyqxmd.com/read/30001924/fingolimod-and-cidp-insights-from-negative-results
#1
Laurent Magy
No abstract text is available yet for this article.
July 6, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/30001923/oral-fingolimod-for-chronic-inflammatory-demyelinating-polyradiculoneuropathy-forcidp-trial-a-double-blind-multicentre-randomised-controlled-trial
#2
Richard Hughes, Marinos C Dalakas, Ingemar Merkies, Norman Latov, Jean-Marc Léger, Eduardo Nobile-Orazio, Gen Sobue, Angela Genge, David Cornblath, Martin Merschhemke, Carolyn Marie Ervin, Catherine Agoropoulou, Hans-Peter Hartung
BACKGROUND: Fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis and was effective in experimental autoimmune neuritis in rats, a possible model for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We aimed to evaluate the efficacy of fingolimod in delaying disability progression in patients with CIDP who withdrew from currently effective treatments (intravenous immunoglobulin [IVIg] or corticosteroids). METHODS: This double-blind, multicentre, randomised, placebo-controlled, parallel-group, event-driven study was done at 48 neurology centres in Australia, Canada, Israel, Japan, the USA, and nine countries in Europe...
July 6, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29954678/a-new-life-after-stroke
#3
Jules Morgan
No abstract text is available yet for this article.
June 25, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29954677/wilder-graves-penfield
#4
Domenico Chirchiglia, Pasquale Chirchiglia, Rosa Marotta
No abstract text is available yet for this article.
June 25, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29934200/myotonic-dystrophy-type-1-reasons-to-be-optimistic
#5
Cynthia Gagnon, Benjamin Gallais, Luc Laberge
No abstract text is available yet for this article.
June 18, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29934199/cognitive-behavioural-therapy-with-optional-graded-exercise-therapy-in-patients-with-severe-fatigue-with-myotonic-dystrophy-type-1-a-multicentre-single-blind-randomised-trial
#6
Kees Okkersen, Cecilia Jimenez-Moreno, Stephan Wenninger, Ferroudja Daidj, Jeffrey Glennon, Sarah Cumming, Roberta Littleford, Darren G Monckton, Hanns Lochmüller, Michael Catt, Catharina G Faber, Adrian Hapca, Peter T Donnan, Gráinne Gorman, Guillaume Bassez, Benedikt Schoser, Hans Knoop, Shaun Treweek, Baziel G M van Engelen
BACKGROUND: Myotonic dystrophy type 1 is the most common form of muscular dystrophy in adults and leads to severe fatigue, substantial physical functional impairment, and restricted social participation. In this study, we aimed to determine whether cognitive behavioural therapy optionally combined with graded exercise compared with standard care alone improved the health status of patients with myotonic dystrophy type 1. METHODS: We did a multicentre, single-blind, randomised trial, at four neuromuscular referral centres with experience in treating patients with myotonic dystrophy type 1 located in Paris (France), Munich (Germany), Nijmegen (Netherlands), and Newcastle (UK)...
June 18, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29934198/safety-and-efficacy-of-rasagiline-as-an-add-on-therapy-to-riluzole-in-patients-with-amyotrophic-lateral-sclerosis-a-randomised-double-blind-parallel-group-placebo-controlled-phase-2-trial
#7
Albert C Ludolph, Joachim Schuster, Johannes Dorst, Luc Dupuis, Jens Dreyhaupt, Jochen H Weishaupt, Jan Kassubek, Ulrike Weiland, Susanne Petri, Thomas Meyer, Julian Grosskreutz, Berthold Schrank, Matthias Boentert, Alexander Emmer, Andreas Hermann, Daniel Zeller, Johannes Prudlo, Andrea S Winkler, Torsten Grehl, Michael T Heneka, Siw Wollebæk Johannesen, Bettina Göricke
BACKGROUND: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole. We sought to test whether or not rasagiline 1 mg/day can prolong survival in patients with amyotrophic lateral sclerosis also receiving riluzole. METHODS: Patients with possible, probable, or definite amyotrophic lateral sclerosis were enrolled to our randomised, placebo-controlled, parallel-group, double-blind, phase 2 trial from 15 German network for motor neuron diseases (MND-NET) centres (university hospitals or clinics)...
June 18, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29934197/when-a-negative-trial-in-als-has-a-positive-effect-on-research
#8
Nazem Atassi
No abstract text is available yet for this article.
June 18, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29903462/has-autism-found-a-place-in-mainstream-tv
#9
Jules Morgan
No abstract text is available yet for this article.
June 11, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29887163/patent-foramen-ovale-in-older-patients-with-cryptogenic-stroke-or-transient-ischaemic-attack
#10
David Thaler
No abstract text is available yet for this article.
June 6, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29887162/prevalence-of-patent-foramen-ovale-in-cryptogenic-transient-ischaemic-attack-and-non-disabling-stroke-at-older-ages-a-population-based-study-systematic-review-and-meta-analysis
#11
Sara Mazzucco, Linxin Li, Lucy Binney, Peter M Rothwell
BACKGROUND: Percutaneous closure of patent foramen ovale (PFO) has been shown to be superior to medical treatment alone for prevention of recurrent stroke after cryptogenic transient ischaemic attack or non-disabling stroke in patients aged 60 years or younger. The justification for trials in older patients with transient ischaemic attack or stroke depends on whether PFO is shown to be associated with cryptogenic events at older ages, for which existing evidence is conflicting, and on the population burden of PFO-associated events...
June 6, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29887160/a-novel-link-between-trafficking-and-lewy-body-disorders
#12
Owen A Ross, Guojun Bu
No abstract text is available yet for this article.
June 6, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29802010/experiencing-life-in-an-asylum
#13
Elena Bozhkova
No abstract text is available yet for this article.
May 22, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29752129/william-alexander-hammond
#14
Ray Cavanaugh
No abstract text is available yet for this article.
May 8, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29735240/out-of-the-ring-boxing-and-long-term-brain-damage
#15
Jules Morgan
No abstract text is available yet for this article.
May 4, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29705251/the-clive-ballard-energy-equation
#16
Adrian Burton
No abstract text is available yet for this article.
April 25, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29681502/augusta-dejerine-klumpke
#17
Vijay Shankar Balakrishnan
No abstract text is available yet for this article.
April 19, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29914709/sex-differences-in-the-evaluation-and-treatment-of-acute-ischaemic-stroke
#18
REVIEW
Cheryl Bushnell, Virginia J Howard, Lynda Lisabeth, Valeria Caso, Seana Gall, Dawn Kleindorfer, Seemant Chaturvedi, Tracy E Madsen, Stacie L Demel, Seung-Jae Lee, Mathew Reeves
With the greater availability of treatments for acute ischaemic stroke, including advances in endovascular therapy, personalised assessment of patients before treatment is more important than ever. Women have a higher lifetime risk of stroke; therefore, reducing potential sex differences in the acute stroke setting is crucial for the provision of equitable and fast treatment. Evidence indicates sex differences in prevalence and types of non-traditional stroke symptoms or signs, prevalence of stroke mimics, and door-to-imaging times, but no substantial differences in use of emergency medical services, stroke knowledge, eligibility for or access to thrombolysis or thrombectomy, or outcomes after either therapy...
July 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29914708/network-imaging-biomarkers-insights-and-clinical-applications-in-parkinson-s-disease
#19
REVIEW
Katharina A Schindlbeck, David Eidelberg
Parkinson's disease presents several practical challenges: it can be difficult to distinguish from atypical parkinsonian syndromes, clinical ratings can be insensitive as markers of disease progression, and its non-motor manifestations are not readily assessed in animal models. These challenges, along with others, are beginning to be addressed by innovative imaging methods to characterise Parkinson's disease-specific functional networks across the whole brain and measure their expression in each patient. These signatures can help improve differential diagnosis, guide selection of patients for clinical trials, and quantify treatment responses and placebo effects in individual patients...
July 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29914707/neurology-in-the-19th-century-the-french-triad
#20
Philippe Charlier, Saudamini Deo
No abstract text is available yet for this article.
July 2018: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"